FDA Approves Alecensa for Lung Cancer

The United States Food and Drug Administration (FDA) has approved the new oral agent Alecensa (alectinib) for the treatment of advanced lung cancer.

Specifically, Alecensa was approved for the treatment of advanced non-small cell lung cancer (NSCLC) that is AKL-positive, and has stopped responding to prior therapy with Xalkori (crizotinib).

The following link is to the press release b y the FDA announcing their approval of Alecensa: